Cidel Asset Management Inc. Buys 5,476 Shares of Eli Lilly and Company $LLY

Cidel Asset Management Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 35.0% in the second quarter, Holdings Channel reports. The institutional investor owned 21,135 shares of the company’s stock after purchasing an additional 5,476 shares during the period. Cidel Asset Management Inc.’s holdings in Eli Lilly and Company were worth $16,475,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. WestEnd Advisors LLC boosted its stake in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter valued at $27,000. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC lifted its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the topic of several research reports. Guggenheim reaffirmed a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. UBS Group cut their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. JPMorgan Chase & Co. dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Finally, HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $939.12.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $803.53 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a fifty day moving average price of $753.09 and a 200-day moving average price of $765.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The firm has a market cap of $760.51 billion, a PE ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $3.92 EPS. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.